Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 466

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 5
Chunk 466
---
 days of the date of this annual report on Form 10-K.

    Name and Address of Beneficial Owner(1) 
    Number of Shares Beneficially Owned  
    Percentage of Outstanding Ordinary Shares 
  
    Drugs Made In America Acquisition LLC(2) 
     4,188,780  
     12.5%
  
    Lynn Stockwell(2) 
     4,188,780  
     12.5%
  
    Glenn Worman 
     100,000  
     * 
  
    Catherine Do 
     100,000  
     * 
  
    G. Sridhar Prasad 
     100,000  
     * 
  
    Myron W. Shulgan 
     100,000  
     * 
  
    All directors and executive officers as a group (5
    individuals) 
     4,588,780  
     13.7%

*Less than 1%

(1)Unless otherwise indicated, the business address of each of
the following entities or individuals is c/o Drugs Made In America Acquisition Corp., 1 East Broward Boulevard, Suite 700, Fort Lauderdale,
FL 33301.

(2)Drugs Made In America Acquisition LLC, our sponsor, is the record
holder of the shares reported herein. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over
the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor,
except to the extent of her pecuniary interest therein.

Restrictions on Transfers of Founder Shares
and Private Placement Units

The founder shares and the Private Placement Units, including the underlying
private shares and private rights, are subject to transfer restrictions pursuant to lock-up provisions in the letter agreement with us
entered into by our initial shareholders. Those lock-up provisions provide that such securities are not transferable or salable until
the earlier of: (i) with respect to 50% of the founder shares and Private Placement Units, the earlier of six months after the date of
the consummation of our initial business combination and the date on which the closing price of our ordinary shares equals or exceeds
$12.50 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any
20 trading days within any 30-trading day period commencing after